Abstract
Primary percutaneous coronary intervention (PCI) encompassing stent implantation is a mainstay in the management of acute ST-elevation myocardial infarction (STEMI). Despite refinements in techniques and devices, peri- and post-procedural antithrombotic therapy remains pivotal to prevent early and late thrombotic events, without unduly increasing bleeding risk. Concomitant dual antiplatelet therapy with aspirin and clopidogrel has been considered until recently the standard of care in terms of oral antiplatelet agents. However, most recently a novel and more potent thienopyridine, prasugrel, has been tested in randomized trials including patients with STEMI, and subsequently approved for clinical practice in Europe and North America. Despite its potent antithrombotic effect, prasugrel also carries a statistically significant increase in the risk of bleeding, especially in the elderly, those with low body weight, and previous stroke or transient ischemic attack. Thus, the use of prasugrel, as well as that of clopidogrel or ticagrelor, should best be individualized to maximize clinical benefits and minimize hazards.
Keywords: Acute coronary syndrome, angioplasty, clopidogrel, myocardial infarction, prasugrel, stent, thienopyridine, stroke, transient ischemic attack, thrombolysis
Current Vascular Pharmacology
Title:Prasugrel During Primary Percutaneous Coronary Intervention: Evidence from Clinical Data
Volume: 10 Issue: 4
Author(s): Giuseppe Biondi-Zoccai, Antonio Abbate, Fabrizio D’Ascenzo, Marzia Lotrionte and Maria G. Modena
Affiliation:
Keywords: Acute coronary syndrome, angioplasty, clopidogrel, myocardial infarction, prasugrel, stent, thienopyridine, stroke, transient ischemic attack, thrombolysis
Abstract: Primary percutaneous coronary intervention (PCI) encompassing stent implantation is a mainstay in the management of acute ST-elevation myocardial infarction (STEMI). Despite refinements in techniques and devices, peri- and post-procedural antithrombotic therapy remains pivotal to prevent early and late thrombotic events, without unduly increasing bleeding risk. Concomitant dual antiplatelet therapy with aspirin and clopidogrel has been considered until recently the standard of care in terms of oral antiplatelet agents. However, most recently a novel and more potent thienopyridine, prasugrel, has been tested in randomized trials including patients with STEMI, and subsequently approved for clinical practice in Europe and North America. Despite its potent antithrombotic effect, prasugrel also carries a statistically significant increase in the risk of bleeding, especially in the elderly, those with low body weight, and previous stroke or transient ischemic attack. Thus, the use of prasugrel, as well as that of clopidogrel or ticagrelor, should best be individualized to maximize clinical benefits and minimize hazards.
Export Options
About this article
Cite this article as:
Biondi-Zoccai Giuseppe, Abbate Antonio, D’Ascenzo Fabrizio, Lotrionte Marzia and G. Modena Maria, Prasugrel During Primary Percutaneous Coronary Intervention: Evidence from Clinical Data, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812782
DOI https://dx.doi.org/10.2174/157016112800812782 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Heart Transplantation in Congenital Heart Disease (Guest Editor: Francesco Parisi)]
Current Cardiology Reviews CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets Apathy: A Conceptual Review
Current Psychiatry Research and Reviews Vascular Calcification in Chronic Kidney Disease: Role of Disordered Mineral Metabolism
Current Pharmaceutical Design Efficacy of the Newest COX-2 Selective Inhibitors in Rheumatic Disease
Current Pharmaceutical Design Functional Roles of Benzothiazole Motif in Antiepileptic Drug Research
Mini-Reviews in Medicinal Chemistry Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components
Current Vascular Pharmacology A Snapshot of Current Updates and Future Prospects of 3D Printing in Medical and Pharmaceutical Science
Current Pharmaceutical Design Amplicon Vectors as Outstanding Tools to Study and Modify Cognitive Functions
Current Gene Therapy Contemporary Management of Deep Vein Thrombosis, Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation The ATP-Binding Cassette Transporter-2 (ABCA2) Overexpression Modulates Sphingosine Levels and Transcription of the Amyloid Precursor Protein (APP) Gene
Current Alzheimer Research Transcription Factors in Asthma: Are Transcription Factors a New Target for Asthma Therapy?
Current Drug Targets Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Coronaviruses Agomelatine: An Astounding Sui-generis Antidepressant?
Current Molecular Pharmacology Therapeutic Approaches for the Management of Sleep Disorders in Geriatric Population
Current Medicinal Chemistry Renal Cytochrome P450-Derived Eicosanoids and Hypertension
Current Hypertension Reviews